Model for predicting the burden and cost of treatment in cervical cancer and HPV-related diseases in Thailand

Purpose: Cervical cancer is a significant health burden in many countries. Long-term cost of care is still not well understood. We aimed to evaluate the long-term burden of illness and healthcare resource utilization associated with cervical cancer, cervical intraepithelial neoplasia (CIN) and genital warts from the care provider perspective. Method: We developed a health state-transition Markov model to portray the algorithm of treatment of stages of cervical cancer, CIN and genital warts by tracking a hypothetical lifetime cohort of 12-year-old girls. Costs in this study were unit cost; capital costs and labor costs were included in the unit cost for in-patients and out-patients. Results: The highest incidence of CIN and genital warts was observed in women aged 20-30 years old. For cervical cancer, the highest incidence was 45-55 years. Death rate was estimated at 2%, 8%, 84% and 94% in cervical cancer Stage IA1, IA2-IIA, I and IVB, respectively. The estimated mean direct cost per patient with cervical cancer Stage IA1, IA2-IIA, IIB-IVA, IVB, CIN1, CIN2/3 and genital warts were 41,117 Thai Baht ($1,277 US), 97,250 Thai Baht ($3,020 US), 402,683 Thai Baht ($12,506 US), 322,619 Thai Baht ($10,019 US), 5,381 Thai Baht ($167 US), 49,933 Thai Baht ($1.551 US) and 3,585 Thai Baht ($111 US), respectively. Cost for survival or death case was indifferent. The overall lifetime costs from the provider perspective were evaluated at 859.1 million Baht ($26.7 million US) per a cohort of 100,000 women which corresponds to approximately 4,244 million Baht ($131.8 million US) for the current number of Thai 12-year-old girls. Conclusions: HPV-related diseases impose health and cost burdens in Thailand. The national immunization programme to reduce this burden as well as further research to evaluate the impact is keenly expected.

Cost; Cervical cancer; HPV-related diseases

[1] Parkin D.M.: “Cancer in developing countries”. Cancer Surv., 1994, 19, 519.

[2] Parkin D.M., Pisani P., Ferlay J.: “Estimates of the worldwide incidence of 25 major cancers in 1990”. Int. J. Cancer, 1999, 80, 827.

[3] Pisani P., Parkin D.M., Ferlay J.: “Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden”. Int. J. Cancer, 1993, 55, 891.

[4] Quinn M.J., Cooper N., Rachet B., Mitry E., Woods L.M., Coleman M.P.: “Survival from cancer of the uterine cervix in England and Wales up to 2001”. Br. J. Cancer, 2008, 99 (suppl. 1), S59.

[5] Thomas G.: “Cervical cancer: treatment challenges in the developing world”. Radiother. Oncol., 2006, 79, 139.

[6] Chichareon S.B.: “Cervical cancer incidence in the south of Thailand 1988-1989”. J. Med. Assoc. Thai, 1993, 76, 146.

[7] Deerasamee S., Srivatanakul P.: “Cervix uteri”. In: Deerasamee S., Martin N., Sontipong S., Sriamporn S. et al. (eds.). Cancer in Thailand 1992-1994, Vol. II. Lyon: IARC Technical report no. 34, 1999, 56.

[8] Pengsaa P., Jindawijak S.: “Cervix uteri”. In: Sriplung H, Sontipong S, Martin N. et al. (eds.). Cancer in Thailand vol III. National Cancer Institute of Thailand, 1997.

[9] Sriplung H.: “Projection of cancer problems”. In: Khuhaprema T., Srivatanakul P., Sriplung H. et al. (eds.). Cancer in Thailand vol. IV. National Cancer Institute of Thailand, 2008.

[10] Srivatanakul P.: “Cervix uteri”. In: Khuhaprema T., Srivatanakul P., Sriplung H. et al. (eds.). Cancer in Thailand vol IV. National Cancer institute of Thailand, 2000, 51.

[11] Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J. et al.: “Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group”. J. Natl. Cancer Inst., 1995, 87, 796.

[12] Lertworapreecha M., Bhattarakosol P., Niruthisard S.: “Detection and typing of human papillomavirus in cervical intraepitherial neoplasia (CIN) grade III by PCR and dot hybridization”. Southeast Asian. J. Trop. Med. Public Health, 1998, 29, 507.

[13] Munoz N., Bosch F.X.: “HPV and cervical neoplasia: review of case-control and cohort studies”. IARC Sci. Publ., 1992, 251.

[14] Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V. et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. J. Pathol., 1999, 189, 12.

[15] Wilailak S.: “Epidemiologic report of gynecologic cancer in Thailand”. J. Gynecol. Oncol., 2009, 20, 81.

[16] Breitburd F., Coursaget P.: “Human papillomavirus vaccines”. Semin. Cancer Biol., 1999, 9, 431.

[17] Burchell A.N., Richardson H., Mahmud S.M., Trottier H., Tellier P.P., Hanley J. et al.: “Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada”. Am. J. Epidemiol., 2006, 163, 534.

[18] Cantor S.B., Fahs M.C., Mandelblatt J.S., Myers E.R., Sanders G.D.: “Decision science and cervical cancer”. Cancer, 2003, 98, 2003.

[19] Goldie S.J., Weinstein M.C., Kuntz K.M., Freedberg K.A.: “The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women”. Ann. Intern. Med., 1999, 130, 97.

[20] Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X. et al.: “Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine”. J. Natl. Cancer Inst., 2004, 96, 604.

[21] Kim J.J., Wright T.C., Goldie S.J.: “Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance”. JAMA, 2002, 287, 2382.

[22] Kulasingam S.L., Myers E.R.: “Potential health and economic impact of adding a human papillomavirus vaccine to screening programs”. JAMA, 2003, 290, 781.

[23] Mandelblatt J.S., Lawrence W.F., Womack S.M., Jacobson D., Yi B., Hwang Y.T. et al.: “Benefits and costs of using HPV testing to screen for cervical cancer”. JAMA, 2002, 287, 2372.

[24] Mandelblatt J.S., Lawrence W.F., Gaffikin L., Limpahayom K.K., Lumbiganon P., Warakamin S. et al.: “Costs and benefits of different strategies to screen for cervical cancer in less-developed countries”. J. Natl. Cancer Inst., 2002, 94, 1469.

[25] Myers E.R., McCrory D.C., Nanda K., Bastian L., Matchar D.B.: “Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis”. Am. J. Epidemiol., 2000, 151, 1158.

[26] Sanders G.D., Taira A.V.: “Cost-effectiveness of a potential vaccine for human papillomavirus”. Emerg. Infect. Dis., 2003, 9, 37.

[27] Taira A.V., Neukermans C.P., Sanders G.D.: “Evaluating human papillomavirus vaccination programs”. Emerg. Infect. Dis., 2004, 10, 1915.

[28] Arveux P., Benard S., Bouee S., Lafuma A., Martin L., Cravello L. et al.: “Invasive cervical cancer treatment costs in France”. Bull. Cancer, 2007, 94, 219.

[29] Hillemanns P., Breugelmans J.G., Gieseking F., Benard S., Lamure E., Littlewood K.J. et al.: “Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study”. BMC Infect. Dis., 2008, 8, 76.

[30] Insinga R.P., Dasbach E.J., Myers E.R.: “The health and economic burden of genital warts in a set of private health plans in the United States”. Clin. Infect. Dis., 2003, 36, 1397.

[31] Pirotta M., Stein A.N., Conway E.L., Harrison C., Britt H., Garland S.: “Genital Warts Incidence and Health Care Resource Utilisation in Australia”. Sex Transm. Infect., 2009.

[32] Ricciardi A., Largeron N., Giorgi R.P., Raffaele M., Cohet C., Federici A. et al.: “Incidence of invasive cervical cancer and direct costs associated with its management in Italy”. Tumori, 2009, 95, 146.

[33] Manusirivithaya S., Sripramote M., Tangjitgamol S., Sanjareonsuttikul N., Pisarnturakit P.: “Cost effectiveness of concurrent chemoradiation in comparison with radiation alone in locally advanced cervical cancer”. J. Med. Assoc. Thai., 2005, 88, 1035.

[34] Doubilet P., Begg C.B., Weinstein M.C., Braun P., McNeil B.J.: “Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach”. Med. Decis. Making, 1985, 5, 157.

[35] Sonnenber F.A., Beck J.R.: “Markov models in medical decision making: a practical guide”. Med. Decision Making, 1993, 13, 322.

[36] Prasartkul P., Rakchanyaban U.: “Estimation generation life tables for Thailand of five-year birth cohorts: 1900-2000”. Bangkok, Thailand: Institute for Population and Social Research, Mahidol University, 2002.

[37] Insinga R.P., Glass A.G., Rush B.B.: “Diagnoses and outcomes in cervical cancer screening: a population-based study”. Am. J. Obstet. Gynecol., 2004, 191, 105.

[38] Tanapat Y., Sungkawasi K., Tatanan K., Buranavit K., Chaiprapa C., Takarnjanavanit S. et al.: “Cervical Cancer Survival at Pramongkutklao Hospital”. Royal Thai Army Med. J.,1995, 48, 21.

[39] Srisupundit S., Kraiphibul P., Tangtrakul S., Bhamarapravati Y:. “Cervical Cancer Survival at Ramathibodi Hospital 1979-1983”. J. Med. Assoc. Thai., 1990, 73 (suppl. 1), 15.

[40] Pengsaa P., Udomthavornsak B., Hemfling A.: “Prognostic factors for survival after surgery for early stages cervical cancer”. Thai J. Obstet. Gynaecol., 1990, 2, 29.

[41] Kongthanarat Y.: “Five year results of radiation therapy and radiation therapy with concomitant high dose Mitomycin-C in the treatment of the uterine cervix”. J. Rajavithi Hosp., 1996, 7, 25.

[42] Zighelboim I., Taylor N.P., Powell M.A., Gibb R.K., Rader J.S., Mutch D.G. et al.: “Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy”. Radiat. Med., 2006, 24, 625.

[43] Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M. et al.: “Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial”. Lancet, 2006, 367, 1247.

[44] Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J. et al.: “Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial”. Obstet. Gynecol., 2006, 107, 18.

[45] Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R. et al.: “Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial”. Lancet Oncol., 2005, 6, 271.

[46] Rossi P.G., Ricciardi A., Cohet C., Palazzo F., Furnari G., Valle S. et al.: “Epidemiology and cost of cervical cancer screening and cervical dysplasia in Italy”. BMC Public Health, 2009, 9, 71.

[47] Lachance J.A., Darus C.J., Stukenborg G.J., Schneider B.F., Rice L.W., Jazaeri A.A.: “A cost comparison of two strategies for treating Stage IB2 cervical cancer”. Int. J. Gynecol. Cancer, 2008, 18, 274.

[48] National Statistical Office of Thailand: Household income, expenditure and debt. Thailand, 2007.